Henning T Mouridsen

Summary

Affiliation: Copenhagen University Hospital
Country: Denmark

Publications

  1. pmc Pathologic examination of sentinel lymph nodes in breast cancer by a single haematoxylin-eosin slide versus serial sectioning and immunocytokeratin staining: clinical implications
    Reinou S Groen
    Department of Surgery, Isala Klinieken, Zwolle, The Netherlands
    Breast Cancer Res Treat 105:1-5. 2007
  2. doi Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer
    Henning T Mouridsen
    Danish Breast Cancer Cooperative Group, Rigshospitalet, Department of Oncology 2501, Blegdamsvej 9, Kobenhavn O 2100, Denmark
    Expert Rev Anticancer Ther 10:1825-36. 2010
  3. doi One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer
    Bent Ejlertsen
    Danish Breast Cancer Cooperative Group DBCG, Rigshospitalet, Copenhagen, Denmark
    Eur J Cancer 49:2986-94. 2013
  4. doi Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer
    Bent Kristensen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 47:740-6. 2008
  5. doi Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer
    Bent Ejlertsen
    Danish Breast Cancer Cooperative Group, Copenhagen, Denmark
    Cancer 116:2081-9. 2010
  6. doi DBCG trial 89B comparing adjuvant CMF and ovarian ablation: similar outcome for eligible but non-enrolled and randomized breast cancer patients
    Bent Ejlertsen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 47:709-17. 2008
  7. pmc Letrozole in advanced breast cancer: the PO25 trial
    Henning T Mouridsen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark
    Breast Cancer Res Treat 105:19-29. 2007
  8. pmc Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer
    Henning T Mouridsen
    Department of Oncology, Rigshospitalet, Copenhagen, Denmark
    MedGenMed 7:20. 2005
  9. ncbi Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women
    Henning T Mouridsen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    Curr Med Res Opin 22:1609-21. 2006
  10. doi Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89
    Bent Ejlertsen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 47:662-71. 2008

Collaborators

Detail Information

Publications18

  1. pmc Pathologic examination of sentinel lymph nodes in breast cancer by a single haematoxylin-eosin slide versus serial sectioning and immunocytokeratin staining: clinical implications
    Reinou S Groen
    Department of Surgery, Isala Klinieken, Zwolle, The Netherlands
    Breast Cancer Res Treat 105:1-5. 2007
    ....
  2. doi Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer
    Henning T Mouridsen
    Danish Breast Cancer Cooperative Group, Rigshospitalet, Department of Oncology 2501, Blegdamsvej 9, Kobenhavn O 2100, Denmark
    Expert Rev Anticancer Ther 10:1825-36. 2010
    ....
  3. doi One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer
    Bent Ejlertsen
    Danish Breast Cancer Cooperative Group DBCG, Rigshospitalet, Copenhagen, Denmark
    Eur J Cancer 49:2986-94. 2013
    ..In addition, we analyse the prognostic and predictive value of centrally assessed subtypes...
  4. doi Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer
    Bent Kristensen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 47:740-6. 2008
    ..The patients received adjuvant chemotherapy, loco-regional radiation therapy, but no endocrine treatment...
  5. doi Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer
    Bent Ejlertsen
    Danish Breast Cancer Cooperative Group, Copenhagen, Denmark
    Cancer 116:2081-9. 2010
    ..The authors report the results from that trial after a potential follow-up of 25 years...
  6. doi DBCG trial 89B comparing adjuvant CMF and ovarian ablation: similar outcome for eligible but non-enrolled and randomized breast cancer patients
    Bent Ejlertsen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 47:709-17. 2008
    ..A cohort of premenopausal patients with primary hormone receptor positive breast cancer was prospectively identified to be eligible for the DBCG 89B trial. We perform a long-term follow-up and evaluate the external validity of the trial...
  7. pmc Letrozole in advanced breast cancer: the PO25 trial
    Henning T Mouridsen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark
    Breast Cancer Res Treat 105:19-29. 2007
    ..Letrozole is the only third-generation aromatase inhibitor that has demonstrated significant improvements in ORR, TTP, and early OS...
  8. pmc Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer
    Henning T Mouridsen
    Department of Oncology, Rigshospitalet, Copenhagen, Denmark
    MedGenMed 7:20. 2005
    ..Other trials continue to investigate some of these adjuvant treatment strategies...
  9. ncbi Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women
    Henning T Mouridsen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    Curr Med Res Opin 22:1609-21. 2006
    ..However, questions remain about their long-term safety. This paper summarizes the adverse events reported in third-generation AI trials and comments on the appropriate management of these drug-induced adverse events in patients...
  10. doi Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89
    Bent Ejlertsen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 47:662-71. 2008
    ..The classical CMF has later been modified as concerns dose and schedule, without formal comparisons in randomised trials between the classical CMF and the modifications...
  11. ncbi The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women
    Henning T Mouridsen
    Department of Oncology, Rigshospitalet, 9 Blegdamsvej, Copenhagen DK 2100, Denmark
    Eur J Cancer 41:1678-89. 2005
    ..A number of trials further evaluating the three adjuvant treatment strategies are ongoing...
  12. ncbi Aromatase inhibitors in advanced breast cancer
    Henning T Mouridsen
    Department of Oncology, Rigshospitalet, Copenhagen, Denmark
    Semin Oncol 31:3-8. 2004
    ..To date, letrozole appears to be the most effective aromatase inhibitor in the first-line advanced breast cancer setting...
  13. doi Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol
    Mogens Blichert-Toft
    The Danish Breast Cancer Cooperative Group, DBCG, Rigshospitalet, Copenhagen, Denmark
    Acta Oncol 47:672-81. 2008
    ..Local failures as a first event consistent with new primaries are strongly associated with BCS, whereas true recurrence predominates after mastectomy...
  14. ncbi Letrozole in the treatment of breast cancer
    Henning T Mouridsen
    Department of Oncology, Rigshospitalet, 9 Blegdamsvej, Copenhagen, DK 2100, Denmark
    Expert Opin Pharmacother 6:1389-99. 2005
    ..Ongoing trials will determine whether the optimal use of letrozole in the adjuvant therapy of early breast cancer is as a replacement for tamoxifen, or sequenced additionally before or after tamoxifen...
  15. doi Improvements in breast cancer survival between 1995 and 2012 in Denmark: The importance of earlier diagnosis and adjuvant treatment
    Maj Britt Jensen
    a Danish Breast Cancer Cooperative Group DBCG Secretariat and Statistical Office, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 55:24-35. 2016
    ..Conclusion The impact of screening was by nature of limited magnitude. The modified treatment strategies implemented by the use of nationwide guidelines seemed to have a major impact on the substantial survival improvements. ..
  16. doi Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer
    Bent Ejlertsen
    Danish Breast Cancer Cooperative Group DBCG Secretariat and Statistical Office, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Acta Oncol 53:174-85. 2014
    ..Furthermore, to identify a subset without excess mortality using clinical and pathological characteristics...
  17. doi The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise
    Susanne Møller
    Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark
    Acta Oncol 47:506-24. 2008
    ..Discussion. The joint conception of the multidisciplinary breast cancer group and a clinical database has provided improvements in the management of breast cancer patients and has enabled recruitment of patients onto randomised trials...
  18. ncbi Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403)
    Bent Ejlertsen
    Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    J Clin Oncol 22:2313-20. 2004
    ..To determine whether the addition of intravenous (IV) vinorelbine to epirubicin increased the progression-free survival in first-line treatment of metastatic breast cancer...